Nitin Roper, M.D., M.Sc.
Dr. Roper is a physician scientist with a research focus on high-grade neuroendocrine tumors, including small cell lung cancers, bladder, prostate, pancreatic and non-small cell cancers that transform to high-grade neuroendocrine cancers. Specifically, Dr. Roper is engaged in translational research aimed at understanding the epigenetic, immunologic and molecular aspects of neuroendocrine differentiation with the goal of translating experimental data to the clinic.
1) high-grade neuroendocrine tumors, 2) small cell lung cancer, 3) tumor heterogeneity,
4) immunotherapy, 5) EGFR mutant non-small cell lung cancer
My overall research goal is to decipher the mechanisms which drive the aggressive clinical behavior of high-grade neuroendocrine tumors including treatment resistance. In particular, I am interested in: 1) deciphering the biologic mechanisms of high-grade neuroendocrine tumors that may, in turn, predict response or lack of response to immune checkpoint inhibition; 2) elucidating the epigenetic mechanisms which drive recurrent, treatment refractory high-grade neuroendocrine tumors; and 3) establishing pre-clinical models of high-grade neuroendocrine tumors. These studies will inform rational combinations to augment both targeted and immunotherapy approaches within high-grade neuroendocrine tumors.
Selected Recent Publications
APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.Cell Reports. 26(10): 2651-2666, 2019. [ Journal Article ]
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study.Journal of Thoracic Oncology. 14(8): 1447-1457, 2019. [ Journal Article ]
Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.Molecular Cellular Proteomics. 18(4): 622-641, 2019. [ Journal Article ]
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.Clinical Cancer Research. 23(14): 3610-3618, 2017. [ Journal Article ]
After completing his undergraduate work at Brown University, Dr. Roper received his M.D. at the University of Connecticut School of Medicine. He completed an internship and residency in internal medicine at Mount Sinai Hospital in New York City. He subsequently obtained a Master’s in Clinical Research Methods from Columbia University, Mailman School of Public Health and was an Instructor in Medicine at Weill Cornell Medical College. He recently completed medical oncology training through the NHLBI-NCI Hematology Oncology Fellowship program and is board certified in Medical Oncology. Dr. Roper joined the Developmental Therapeutics Branch as an Assistant Clinical Investigator in 2019.